A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer

NCT06979908 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Fruquintinib+Sintilimab+Chidamide

Sponsor

The First Hospital of Jilin University